CNTBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Connect Biopharma Holdings Ltd
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.90−0.01 (-0.72%)
Close on Oct 19, 2026
- Market cap
- $56.58M
- P/E (TTM)
- –
- Dividend yield
- –
Connect Biopharma statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Connect Biopharma | Industry median |
|---|---|---|
| Market Cap | $56.66M | $164.85M |
| Enterprise Value | $25.16M | $87.06M |
| PS Ratio | 19.19 | 3.60 |
| PB Ratio | 2.11 | 2.03 |
| P/TBV Ratio | 2.11 | 2.31 |
Enterprise value
| Measure | Connect Biopharma | Industry median |
|---|---|---|
| EV / Sales | 8.52 | 2.43 |
Income (trailing twelve months)
| Measure | Connect Biopharma | Industry median |
|---|---|---|
| Revenue | $2.95M | $57.94M |
| Operating Income | -$70.41M | -$21.44M |
| Pretax Income | -$68.80M | -$14.45M |
| Net Income | -$68.99M | -$22.46M |
| EBITDA | -$69.73M | -$16.91M |
| EPS (Diluted) | -$1.19 | -$0.83 |
Margins
| Measure | Connect Biopharma | Industry median |
|---|---|---|
| Operating Margin | -2384.5% | -44.5% |
| Pretax Margin | -2329.7% | -13.0% |
| Profit Margin | -2336.3% | -39.2% |
| EBITDA Margin | -2361.3% | -31.3% |
| FCF Margin | -2053.3% | -8.85% |
Returns
| Measure | Connect Biopharma | Industry median |
|---|---|---|
| Return on Equity (ROE) | -140.5% | -53.1% |
| Return on Assets (ROA) | -109.3% | -41.0% |
| Return on Capital Employed (ROCE) | -259.2% | -37.8% |
Growth
| Measure | Connect Biopharma | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 50.3% | 6.01% |
Balance sheet
| Measure | Connect Biopharma | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $31.50M | $62.42M |
| Net Cash (Debt) | $31.50M | $15.68M |
| Net Cash Per Share | $0.50 | $0.66 |
| Equity (Book Value) | $26.86M | $48.79M |
| Book Value Per Share | $0.43 | $1.36 |
| Tangible Book Value | $26.82M | $23.06M |
| Working Capital | $22.32M | $75.77M |
Financial position
| Measure | Connect Biopharma | Industry median |
|---|---|---|
| Current Ratio | 2.37 | 3.30 |
| Quick Ratio | 2.11 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Connect Biopharma | Industry median |
|---|---|---|
| Operating Cash Flow | -$60.58M | -$12.35M |
| Capital Expenditures | -$50.00K | -$1.06M |
| Free Cash Flow | -$60.63M | -$20.28M |
| FCF Per Share | -$0.96 | -$0.42 |
Efficiency
| Measure | Connect Biopharma | Industry median |
|---|---|---|
| Asset Turnover | 0.05 | 0.38 |
Dividends and yields
| Measure | Connect Biopharma | Industry median |
|---|---|---|
| Earnings Yield | -121.8% | -22.7% |
| FCF Yield | -107.0% | -9.07% |
Shares
| Measure | Connect Biopharma | Industry median |
|---|---|---|
| Shares Outstanding | 62,974,300 | 58,179,650 |
| Shares Change (YoY) | 4.43% | 11.1% |
| Shares Change (QoQ) | 0.42% | 0.54% |
| Float | 43,083,600 | 49,173,100 |
| Shares Held by Insiders | 31.6% | 11.6% |
Taxes
| Measure | Connect Biopharma | Industry median |
|---|---|---|
| Income Tax | $196.00K | $91.50K |
Scores
| Measure | Connect Biopharma | Industry median |
|---|---|---|
| Altman Z-Score | -16.70 | -0.24 |
| Piotroski F-Score | 1 | 4 |
Calculated by StockData from Connect Biopharma's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.